uniQure N.V. reported its financial results for the second quarter of 2026, revealing a total revenue of $5.8 million, a 10% increase from $5.3 million in the same period last year. For the first half of 2026, the company generated $9.4 million in revenue, up from $6.8 million in the first half of 2025. Despite this growth in revenue, uniQure experienced a net loss of $81.1 million for the quarter, compared to a loss of $37.7 million in the prior year. The six-month net loss also widened to $134.6 million from $81.4 million year-over-year, primarily driven by increased operating expenses.
The company's operating expenses for the second quarter totaled $51.7 million, up from $49.5 million in the same quarter of 2025. Research and development expenses decreased slightly to $34.0 million from $35.4 million, while selling, general, and administrative expenses rose significantly to $17.4 million from $13.5 million, reflecting higher personnel costs associated with preparations for potential product launches. The increase in administrative expenses was attributed to a higher headcount and related costs as the company gears up for the commercialization of its lead product candidate, AMT-130.
In terms of strategic developments, uniQure successfully completed a follow-on public offering in June 2026, raising net proceeds of $242.7 million. This capital infusion is expected to support the company's ongoing clinical trials and the potential commercialization of AMT-130, a gene therapy for Huntington's disease. The company also amended its loan agreement with Hercules Capital, extending the draw period for a $100 million term loan tranche to September 2027, which provides additional financial flexibility.
Operationally, uniQure reported a total of 69,366,412 ordinary shares outstanding as of June 30, 2026. The company is advancing its clinical pipeline, which includes AMT-130, AMT-260 for refractory mesial temporal lobe epilepsy, and AMT-191 for Fabry disease. The company is currently conducting Phase I/II clinical trials for these candidates, with AMT-130 showing promising results in slowing disease progression. The company anticipates submitting a Biologics License Application (BLA) for AMT-130 in the third quarter of 2026, contingent on ongoing discussions with regulatory authorities.
Looking ahead, uniQure's management expressed confidence in its financial position, stating that the current cash and investment securities of approximately $811.9 million should be sufficient to fund operations into 2030. However, the company acknowledged the potential need for additional financing to support its clinical development and commercialization efforts, particularly if regulatory milestones are not met as planned. The outlook remains cautiously optimistic, with a focus on advancing its gene therapy candidates and navigating the complexities of regulatory approvals.
About uniQure N.V.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov